Lu Lu
University of Science and Technology(YE)Shanghai Medical College of Fudan University(CN)Capital University(US)Army Medical University(CN)Qilu University of Technology(CN)University of Tennessee Health Science Center(US)Guilin Medical University(CN)Capital Medical University(CN)Xiamen University(CN)University of Washington(US)Fudan University(CN)Wenzhou Medical University(CN)Yale University(US)Zhumadian Central Hospital(CN)Shanghai University of Traditional Chinese Medicine(CN)Center for Children(US)Shanghai Public Health Clinical Center(CN)National Center for Women and Children’s Health, China CDC(CN)Guangxi University of Chinese Medicine(CN)Beijing Children’s Hospital(CN)State Key Laboratory of Respiratory Disease(CN)Huashan Hospital(CN)University of Hong Kong(HK)Guangzhou Medical University(CN)
Publications by Year
Research Areas
SARS-CoV-2 and COVID-19 Research, HIV Research and Treatment, HIV/AIDS drug development and treatment, COVID-19 Clinical Research Studies, Animal Virus Infections Studies
Most-Cited Works
- → Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion(2020)1,423 cited
- → Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody(2020)1,271 cited
- → Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein(2020)752 cited
- → Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications(2020)740 cited
- → A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike(2019)521 cited
- → AXL is a candidate receptor for SARS-CoV-2 that promotes infection of pulmonary and bronchial epithelial cells(2021)502 cited